Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01706523 · Seaside Therapeutics, Inc. · PHASE3 · terminated · last registry update 2013-07-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Seaside Therapeutics, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GABBR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2014-05-16Also stopped (withdrawn): University of Manitoba, Baclofen (NCT00493428)
- 2014-03-31Results posted on the registry: University of Utah, Sodium Oxybate (NCT00931164)
- 2014-03-28Phase 3 first posted: University of Rochester, Amitriptyline + Baclofen (NCT02099006)
- 2014-02-03Phase 3 first posted: Denver Health and Hospital Authority, Baclofen + Placebo (NCT02052440)
- 2013-11-25Results posted on the registry: Jazz Pharmaceuticals, Xyrem (sodium oxybate) oral solution (NCT00132873)
- 2013-10-17Results posted on the registry: Brown University, Baclofen + Cyproheptadine (NCT01076283)
- 2013-09-12Also stopped (terminated): Centre for Addiction and Mental Health, Baclofen 30 mg/day + placebo pill (NCT01228994)
- 2013-07-31Also stopped (terminated): Seaside Therapeutics, Inc., arbaclofen (NCT01555333)
- 2013-06-14Results posted on the registry: Seaside Therapeutics, Inc., Arbaclofen (NCT00846547)
- 2013-05-06Results posted on the registry: Seaside Therapeutics, Inc., STX209 + Placebo (NCT00788073)
- 2013-05-01Phase 3 first posted: RVL Pharmaceuticals, Inc., arbaclofen (NCT01844232)
- 2013-03-18Results posted on the registry: AstraZeneca, AZD3355 (NCT00394472)
- 2013-02-12Phase 3 first posted: Bioprojet, BF2.649 (NCT01789398)
- 2012-12-20Also stopped (terminated): Seaside Therapeutics, Inc., Arbaclofen (NCT01013480)
- 2012-12-20Also stopped (terminated): Seaside Therapeutics, Inc., arbaclofen (NCT01064973)
- 2012-12-06Phase 3 first posted: RVL Pharmaceuticals, Inc., arbaclofen + baclofen (NCT01743651)
- 2012-11-30Phase 3 first posted: Ethypharm, Baclofen + Placebo (for baclofen) (NCT01738282)
- 2012-10-22Phase 3 first posted: South West Sydney Local Health District, Baclofen 30mg/day + Baclofen 75mg/day (NCT01711125)
- 2012-09-07Also stopped (withdrawn): State University of New York - Upstate Medical University, Xyrem (NCT00330291)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision